James P Rizzi

USPTO Granted Patents = 44 (Patent Applications = 6)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 14 (Patent Applications = 2)

Average Co-Inventor Count = 4.0

ph-index = 14

Forward Citations = 1,212(Granted Patents)

Location History:

Groton, CT (US) (1990)
Waterford, CT (US) (1984 - 1993)
Niwot, CO (US) (1999 - 2003)
Longmont, CO (US) (2006 - 2012)
Boulder, CO (US) (2010 - 2015)
Addison, TX (US) (2014 - 2020)
Aurora, CO (US) (2023)
Irving, TX (US) (2018 - 2024)

Company Filing History:

Peloton Therapeutics, Inc.

Years Active: 1984-2025

Loading Chart...

44 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12331068 - Compositions and methods for inhibiting CD73 (2025-06-17),

2. RE49948 - Aryl ethers and uses thereof (2024-04-30),

3. 11591355 - CD73 inhibitors and uses thereof (2023-02-28),

4. 10807948 - Aromatic compounds and uses thereof (2020-10-20),

5. 10669269 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2020-06-02),

6. 10597366 - Aryl ethers and uses thereof (2020-03-24),

7. 10144711 - Aryl ethers and uses thereof (2018-12-04),

8. 10040767 - Benzimidazole derivatives and uses thereof (2018-08-07),

9. 9969689 - Aryl ethers and uses thereof (2018-05-15),

10. 9908845 - Aryl ethers and uses thereof (2018-03-06),

11. 9896418 - Aryl ethers and uses thereof (2018-02-20),

12. 9884843 - Cyclic sulfone and sulfoximine analogs and uses thereof (2018-02-06),

13. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2017-11-07),

14. 9174981 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2015-11-03),

15. 8841455 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors (2014-09-23),

Title: Innovator Spotlight: James P. Rizzi

Introduction:

James P. Rizzi is a prolific inventor based in Boulder, Colorado, who has made significant contributions to the field of pharmaceutical sciences. With a remarkable total of 33 patents to his name, Rizzi's work primarily revolves around developing innovative compounds that serve as therapeutic agents for various medical conditions.

Latest Patents:

Among his latest inventions are the patented compounds characterized as substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, recognized as type III receptor tyrosine kinase inhibitors. These compounds have shown promise in serving as inhibitors of cFMS and are indicated for use in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain, and burns in mammals. Such advancements highlight his commitment to addressing complex health challenges through innovative drug design.

Career Highlights:

James P. Rizzi has cultivated a successful career, working with renowned companies such as Array Biopharma Inc. and Pfizer Corporation. His involvement in these prominent organizations has allowed him to push the boundaries of pharmaceutical research and contribute to significant medical advancements.

Collaborations:

Throughout his career, Rizzi has collaborated with notable professionals in the industry, including Mark C. Munson and Martha E. Rodriguez. These partnerships have enabled the cross-pollination of ideas and innovation, further enhancing the impact of his research and patents.

Conclusion:

James P. Rizzi's innovative spirit and dedication to advancing medical science through his numerous patents are commendable. His contributions not only reflect his expertise in pharmaceutical research but also his commitment to improving health outcomes. As he continues to develop new therapeutic agents, the medical community eagerly anticipates the potential impacts of his future inventions.

This text is generated by artificial intelligence and may not be accurate.